Cartesian Therapeutics (RNAC) Shares Outstanding (Diluted Average) (2019 - 2025)
Historic Shares Outstanding (Diluted Average) for Cartesian Therapeutics (RNAC) over the last 7 years, with Q3 2025 value amounting to $26.0 million.
- Cartesian Therapeutics' Shares Outstanding (Diluted Average) rose 2110.47% to $26.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.0 million, marking a year-over-year increase of 2110.47%. This contributed to the annual value of $17.4 million for FY2024, which is 23572.29% up from last year.
- Per Cartesian Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $26.0 million for Q3 2025, which was up 2110.47% from $26.4 million recorded in Q2 2025.
- Cartesian Therapeutics' Shares Outstanding (Diluted Average)'s 5-year high stood at $152.8 million during Q3 2022, with a 5-year trough of $5.1 million in Q1 2023.
- In the last 5 years, Cartesian Therapeutics' Shares Outstanding (Diluted Average) had a median value of $26.0 million in 2025 and averaged $63.0 million.
- In the last 5 years, Cartesian Therapeutics' Shares Outstanding (Diluted Average) plummeted by 9662.4% in 2023 and then skyrocketed by 37843.65% in 2025.
- Quarter analysis of 5 years shows Cartesian Therapeutics' Shares Outstanding (Diluted Average) stood at $114.3 million in 2021, then rose by 27.59% to $145.9 million in 2022, then plummeted by 96.46% to $5.2 million in 2023, then skyrocketed by 235.72% to $17.4 million in 2024, then soared by 49.8% to $26.0 million in 2025.
- Its last three reported values are $26.0 million in Q3 2025, $26.4 million for Q2 2025, and $25.9 million during Q1 2025.